Seeking participants with moderately to severely active ulcerative colitis

The VEGA study – A clinical trial to assess the safety and effectiveness of a combination therapy for ulcerative colitis

The purpose of this study is to see if guselkumab and golimumab when used together is safe and effective for treating participants with moderately to severely active ulcerative colitis (UC). 

Guselkumab has been approved in the USA, the European Union (EU), Canada, and several other countries, including the Australian health authority (Therapeutic Goods Administration), for the treatment of adult patients with moderate to severe plaque psoriasis. In addition, guselkumab is being studied for the treatment of psoriatic arthritis, Crohn’s disease, and paediatric psoriasis. 

Golimumab  has been approved in countries worldwide, including the Therepeutic Goods Administration, for the indications of moderately to severely active ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Anticipated date the enrolment will close: December 2020

Who can take part

Inclusion criteria

  • 18 to 65 years of age
  • Clinical diagnosis of ulcerative colitis

Exclusion criteria

  • Presence of stoma
  • Presence of history of fistula

What is involved for you

Medical History, Physical Exam, Electrocardiogram (ECG), Weight, Height, Blood Pressure, Pulse, Heart Rate, Health Questionnaires, Blood Samples, Urine Test, Colonoscopy with biopsy collection, Stool Tests

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4

For more information

Quote reference number
2018.362
Nicola Dalgliesh
03 9342 8441
Zafirah Khan
03 9342 8995